keyword
MENU ▼
Read by QxMD icon Read
search

Central retinal vein

keyword
https://www.readbyqxmd.com/read/28549848/relationship-between-visual-acuity-and-retinal-thickness-during-anti-vascular-endothelial-growth-factor-therapy-for-retinal-diseases
#1
William C Ou, David M Brown, John F Payne, Charles C Wykoff
PURPOSE: Investigate the relationship between best-corrected visual acuity (BCVA) and central retinal thickness (CRT) in eyes receiving ranibizumab for three common retinal diseases. DESIGN: Retrospective analysis of clinical trial data METHODS: Early Treatment Diabetic Retinopathy Study BCVA and spectral-domain optical coherence tomography measured CRT of 387 eyes of 345 patients enrolled in six prospective clinical trials for management of neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) were evaluated by Pearson correlation and linear regression...
May 23, 2017: American Journal of Ophthalmology
https://www.readbyqxmd.com/read/28546695/retinal-vascular-occlusion-secondary-to-retrobulbar-injection-case-report-and-literature-review
#2
Dhaivat Vasavada, Prabu Baskaran, Seema Ramakrishnan
Retrobulbar injection has been widely practiced as a technique of ocular anesthesia for many decades. Nevertheless, the technique is not free from complications. Vascular occlusion secondary to retrobulbar injection is rare but can be vision threatening. We report a case series of two such patients who presented with poor vision following retrobulbar injection. Fundus showed pale retina with cherry red spot suggestive of central retinal artery occlusion in case 1 and pale disc with sclerosed vessels and multiple superficial hemorrhages suggestive of a combined occlusion of retinal artery and vein in case 2...
January 2017: Middle East African Journal of Ophthalmology
https://www.readbyqxmd.com/read/28541960/clinical-features-of-treated-and-untreated-type-1-idiopathic-macular-telangiectasia-without-the-occurrence-of-secondary-choroidal-neovascularization-followed-for-2-years-in-japanese-patients
#3
Rie Osaka, Chieko Shiragami, Aoi Ono, Mamoru Kobayashi, Yukari Takasago, Ayana Yamashita, Akitaka Tsujikawa
PURPOSE: To evaluate the clinical features of Type 1 idiopathic macular telangiectasia (IMT) followed up for 2 years. METHODS: Forty-nine patients with unilateral Type 1 IMT were examined. Thirty-one IMT eyes were treated with direct laser photocoagulation and/or intravitreal bevacizumab; the remaining 18 eyes, with good vision or slight macular edema, were untreated. Changes in best-corrected visual acuity and central retinal thickness between baseline and 24 months after the initial visit were examined...
May 24, 2017: Retina
https://www.readbyqxmd.com/read/28540655/a-review-of-subthreshold-micropulse-laser-for-treatment-of-macular-disorders
#4
REVIEW
Paula Scholz, Lebriz Altay, Sascha Fauser
Micropulse laser treatment is an alternative to the conventional continuous-wave laser for the treatment of retinal or macular diseases. In contrast to the conventional laser, the therapeutic effect of the subthreshold micropulse laser is not accompanied by thermal retinal damage. This fact is of particular importance when a treatment near the fovea is required. Micropulse treatment is applied in indications such as central serous chorioretinopathy (CSC), diabetic macular edema (DME), or macular edema due to retinal vein occlusion (RVO)...
May 24, 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28538263/better-prognosis-for-eyes-with-preserved-foveal-depression-after-intravitreal-ranibizumab-injection-for-macular-edema-secondary-to-central-retinal-vein-occlusion
#5
Shuta Kitagawa, Shunsuke Yasuda, Yasuki Ito, Shinji Ueno, Takeshi Iwase, Hiroko Terasaki
PURPOSE: To determine the prognosis of eyes with central retinal vein occlusion that had a preserved foveal depression at the baseline and were treated by intravitreal ranibizumab injections (IRIs). METHODS: The authors reviewed the medical records of 23 eyes of 23 consecutive treatment-naive patients who received IRIs to treat the macular edema due to central retinal vein occlusion. Eyes were classified by the pre-IRI presence or absence of a foveal depression...
May 18, 2017: Retina
https://www.readbyqxmd.com/read/28535531/comparison-of-intravitreal-ranibizumab-aflibercept-and-dexamethasone-implant-after-bevacizumab-failure-in-macular-edema-secondary-to-retinal-vascular-occlusions
#6
Joel Hanhart, Yaacov Rozenman
PURPOSE: To compare the visual and anatomic outcomes of macular edema secondary to retinal vein occlusion after switching from bevacizumab to ranibizumab, aflibercept, or dexamethasone implant. METHODS: Fifteen eyes were switched to ranibizumab, 12 to aflibercept, and 10 to dexamethasone. At 3, 6, 9, and 12 months, the outcome measures were visual acuity (VA) and central macular thickness (CMT). RESULTS: One year after the switch, CMT decreased from 430...
May 24, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28525562/retinal-vein-occlusion-as-the-surrogate-marker-for-premature-brain-aging-in-young-patients
#7
Kwan Hyuk Cho, Chi Kyung Kim, Kyungmi Oh, Seung-Won Oh, Kyu Hyung Park, Sang Jun Park
Purpose: We investigated cerebral small vessel disease (SVD) in patients with incidental retinal vein occlusion (RVO). Methods: This retrospective, case-control, observational trial included 125 patients with RVO who underwent brain magnetic resonance imaging (MRI) and 1105 age-matched controls who underwent comprehensive medical interviews and MRI. Underlying cardiovascular diseases and MRI findings were investigated in the patients with RVO according to age (<60 or ≥60 years) and RVO occlusion level (central or branch)...
May 1, 2017: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/28524135/-selective-symptomatic-therapy-of-macular-edema-due-to-occlusive-processes-in-retinal-venous-system
#8
M M Bikbov, R R Fayzrakhmanov, T R Gil'manshin
AIM: to evaluate the effect of dexamethasone intravitreal implant on the functional state of the eye in macular edema associated with central retinal vein occlusion. MATERIAL AND METHODS: The study included two groups of patients: group 1 (control group) - 8 patients (16 eyes) without ocular pathology and group 2 (study group) - 8 patients (8 eyes) with macular edema on the background of newly diagnosed thrombosis of the central retinal vein. All the patients from the study group underwent insertion of an intravitreal dexamethasone implant - Ozurdex...
2017: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/28520638/effects-of-intravitreal-ranibizumab-and-bevacizumab-on-the-retinal-vessel-size-in-diabetic-macular-edema
#9
Muhammed Mustafa Kurt, Osman Çekiç, Çetin Akpolat, Mustafa Elçioglu
PURPOSE: The goal of this study was to assess the effects of a single injection of intravitreal ranibizumab (RAN) or bevacizumab (BEV) on the retinal vessel size in eyes with diabetic macular edema. MATERIALS AND METHODS: In total, 32 patients were enrolled in the RAN group, and 30 patients were included in BEV group. Each of these groups was also subdivided into two others groups: a study group and a control group. The study groups were composed of the injected eyes, whereas the noninjected fellow eyes served as the control groups...
May 16, 2017: Retina
https://www.readbyqxmd.com/read/28507362/visual-outcome-of-retinal-vein-occlusion-in-patients-residing-at-high-altitude
#10
Ahsan Mukhtar, Muhammad Saim Khan, Asad Habib, Mazhar Ishaq, Omer Farooq
OBJECTIVE: To study visual outcome in patients of high altitude retinopathy presenting with retinal venous occlusion. METHODS: The randomised clinical trial study was conducted at the Armed Forces Institute of Ophthalmology, Rawalpindi, Pakistan, from January 2013 to December 2015, and comprised eyes of lowlanders. Patients staying at high altitude (>8,000 feet above sea level) as part of their service duty and presented with retinal venous occlusive disease were included...
May 2017: JPMA. the Journal of the Pakistan Medical Association
https://www.readbyqxmd.com/read/28503435/evaluation-of-hyperreflective-foci-as-a-prognostic-factor-of-visual-outcome-in-retinal-vein-occlusion
#11
Bin Mo, Hai-Ying Zhou, Xuan Jiao, Feng Zhang
AIM: To evaluate the potential role of hyperreflective foci (HF) as a prognostic indicator of visual outcome in patients with macular edema (ME) due to retinal vein occlusion (RVO). METHODS: We retrospectively reviewed 50 eyes of 50 patients with ME due to ischemic central retinal vein occlusion (CRVO), non-ischemic CRVO and branch retinal vein occlusion (BRVO) who were treated with anti-vascular endothelial growth factor (anti-VEGF) at Beijing Tongren Eye Center from January 2013 to July 2016...
2017: International Journal of Ophthalmology
https://www.readbyqxmd.com/read/28499055/sequential-sterile-intraocular-inflammation-associated-with-consecutive-intravitreal-injections-of-aflibercept-and-ranibizumab
#12
Dilraj S Grewal, Tayler Schwartz, Sharon Fekrat
The authors report the unique response of two patients treated for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO) who developed sequential episodes of likely sterile inflammatory responses following separate intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) despite multiple previous uneventful injections for CME secondary to CRVO. Following the twenty-fifth aflibercept and seventh ranibizumab injection, two patients developed an acute inflammatory response, which was treated empirically with intravitreal antibiotics and topical and oral steroids (in Case 2)...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28496301/short-term-outcomes-in-patients-with-branch-retinal-vein-occlusion-who-received-intravitreal-aflibercept-with-or-without-intravitreal-ranibizumab
#13
Yoshihito Sakanishi, Ayumi Usui-Ouchi, Kazunori Tamaki, Keitaro Mashimo, Rei Ito, Nobuyuki Ebihara
PURPOSE: The purpose of this study was to determine the short-term outcomes for patients who received intravitreal aflibercept (IVA) with or without intravitreal ranibizumab (IVR) for macular edema (ME) due to branch retinal vein occlusion (BRVO). PATIENTS AND METHODS: Patients received IVA for ME due to BRVO. Patients who initially received IVA were defined as the treatment-naïve group and those who were switched from IVR to IVA after ME recurrence were defined as the switching group...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28492939/treatment-of-macular-edema-due-to-central-retinal-vein-occlusion-another-score-for-repackaged-bevacizumab
#14
Neil M Bressler
No abstract text is available yet for this article.
May 23, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28492910/effect-of-bevacizumab-vs-aflibercept-on-visual-acuity-among-patients-with-macular-edema-due-to-central-retinal-vein-occlusion-the-score2-randomized-clinical-trial
#15
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Carl C Awh, Derek Y Kunimoto, Dennis M Marcus, John J Wroblewski, Jacqueline King
Importance: Studies have established the efficacy and safety of aflibercept for the treatment of macular edema due to central retinal vein occlusion. Bevacizumab is used off-label to treat this condition despite the absence of supporting data. Objective: To investigate whether bevacizumab is noninferior to aflibercept for the treatment of macular edema secondary to central retinal or hemiretinal vein occlusion. Design, Setting, and Participants: The SCORE2 randomized noninferiority clinical trial was conducted at 66 private practice or academic centers in the United States, and included 362 patients with macular edema due to central retinal or hemiretinal vein occlusion who were randomized 1:1 to receive aflibercept or bevacizumab...
May 23, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28492860/baseline-factors-associated-with-6-month-visual-acuity-and-retinal-thickness-outcomes-in-patients-with-macular-edema-secondary-to-central-retinal-vein-occlusion-or-hemiretinal-vein-occlusion-score2-study-report-4
#16
Ingrid U Scott, Paul C VanVeldhuisen, Michael S Ip, Barbara A Blodi, Neal L Oden, Jacqueline King, Andrew N Antoszyk, Mark A Peters, Michael Tolentino
Importance: Macular edema (ME) is the leading cause of decreased visual acuity (VA) associated with retinal vein occlusion (RVO). Identifying factors associated with better outcomes in RVO eyes treated with anti-vascular endothelial growth factor (VEGF) therapy may provide information useful in counseling patients. Objective: To investigate baseline characteristics associated with 6-month VA and central subfield thickness (CST) outcomes in participants in the Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)...
May 9, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492822/comparing-anti-vascular-endothelial-growth-factor-therapies-for-central-retinal-vein-occlusion
#17
Jennifer K Sun
No abstract text is available yet for this article.
May 9, 2017: JAMA Ophthalmology
https://www.readbyqxmd.com/read/28492435/clinical-findings-of-eyes-with-macular-edema-associated-with-branch-retinal-vein-occlusion-refractory-to-ranibizumab
#18
Taiji Hasegawa, Taizo Kawano, Ichiro Maruko, Hideki Koizumi, Tomohiro Iida
PURPOSE: To determine the relationship between the clinical findings and the response to ranibizumab therapy in eyes with macular edema associated with branch retinal vein occlusion. METHODS: We reviewed the medical records of 68 patients with macular edema associated with a branch retinal vein occlusion. The patients were placed in the refractory group if the central foveal thickness remained more than 250 μm throughout the 6-month study period despite the ranibizumab therapy; otherwise, they were placed in the responsive group...
May 10, 2017: Retina
https://www.readbyqxmd.com/read/28489696/predictors-of-refractory-macular-edema-after-branch-retinal-vein-occlusion-following-intravitreal-bevacizumab
#19
Byung Gil Moon, Ah Ran Cho, You Na Kim, June-Gone Kim
PURPOSE: To evaluate the predictors of refractory macular edema (ME) that develops despite multiple bevacizumab injections in patients with branch retinal vein occlusion (BRVO). METHODS: A total of 107 patients who followed at least 2 years were assigned to 2 groups: a refractory group (n = 56) and a responsive group (n = 51). Baseline characteristics, treatment response at 3 months, and fluorescein angiographic findings at 6 months were compared. Then we tried to identify factors associated with refractory ME development...
May 9, 2017: Retina
https://www.readbyqxmd.com/read/28475051/predicting-macular-edema-recurrence-from-spatio-temporal-signatures-in-optical-coherence-tomography-images
#20
Wolf-Dieter Vogl, Sebastian M Waldstein, Bianca S Gerendas, Ursula Schmidt-Erfurth, Georg Langs
Prediction of treatment responses from available data is key to optimizing personalized treatment. Retinal diseases are treated over long periods and patients' response patterns differ substantially, ranging from a complete response to a recurrence of the disease and need for re-treatment at different intervals. Linking observable variables in high-dimensional observations to outcome is challenging. In this paper, we present and evaluate two different data-driven machine learning approaches operating in a high-dimensional feature space: sparse logistic regression and Random Forests based extra trees (ET)...
May 2, 2017: IEEE Transactions on Medical Imaging
keyword
keyword
53072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"